A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies

British Journal of Cancer

Volumn 110, Issue 10, 2014, Pages 2434-2440

  Lin, C C ^a   Su, W C ^b   Yen, C J ^b   Hsu, C H ^a,c   Su, W P ^b   Yeh, K H ^a,c   Lu, Y S ^a   Cheng, A L ^a,c   Huang, D C L ^d   Fritsch, H ^e   Voss, F ^e   Taube, T ^e   Yang, J C H ^a,c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d Medical Department   (Taiwan)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; POLO LIKE KINASE INHIBITOR; VOLASERTIB;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASIAN; DECREASED APPETITE; DIZZINESS; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPOKALEMIA; ILEUS; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; NEUTROPENIA; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; TINNITUS; URETER CANCER;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; HEMATOLOGIC DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PTERIDINES; SALVAGE THERAPY; TAIWAN; TREATMENT OUTCOME;

EID: 84900540918     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.195     Document Type: Article

References (19)

1. Doi T Murakami H Wan K Miki M Kotani H Sakamoto N Yamamoto N Okano Y 2011 A first-in-human phase I dose-escalation study of MK-1496, first-in-class orally available novel PLK1 inhibitor, in patients w ith advanced solid tumors J Clin Oncol 29(15-suppl): Abstract 3012.
2. Frost A, Mross K, Steinbild S, Hedbom S, Unger C, Kaiser R, Trommeshauser D, Munzert G (2012) Phase I study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours. Curr Oncol 19: E28-e35.
3. Garland LL, Taylor C, Pilkington DL, Cohen JL, Von Hoff DD (2006) A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors. Clin Cancer Res 12: 5182-5189.
4. Hikichi Y, Honda K, Hikami K, Miyashita H, Kaieda I, Murai S, Uchiyama N, Hasegawa M, Kawamoto T, Sato T, Ichikawa T, Cao S, Nie Z, Zhang L, Yang J, Kuida K, Kupperman E (2012) TAK-960, a novel, orally available, selective inhibitor of polo-like kinas e 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens. Mol Cancer Ther 11: 700-709.
5. Hofheinz RD, Al-Batran SE, Hochhaus A, Jäger E, Reichardt VL, Fritsch H, Trommeshaus er D, Munzert G (2010) An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors. Clin Cancer Res 16: 4666-4674.
6. Kang SH, Ahn CW (2002) An invest igation of the traditional algorithm-based designs for Phase 1 cancer trials. Drug Inf J 36: 865-873.
7. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Amer Statist Assoc 53: 457-481.
8. Liu X, Erikson RL (2003) Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 100: 5789-5794.
9. Medema RH, Lin CC, Yang JC (2 011) Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC. Clin Cancer Res 17: 6459-6466.
10. Mross K, Frost A, Steinbild S, Hedbom S, Rentschler J, Kaiser R, Rouyrre N, Trommeshauser D, Hoesl CE, Munzert G (2008) Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 26: 5511-5517.
11. Olmos D, Barker D, Sharma R, Brunetto AT, Yap TA, Taegtmeyer AB, Barriuso J, Medani H, Degenhardt YY, Allred AJ, Smith DA, Murray SC, Lampkin TA, Dar MM, Wilson R, De Bono JS, Blagden SP (2011) Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res 17: 3420-3430.
12. Rudolph D, Steegmaier M, Hoffmann M, Grauert M, Baum A, Quant J, Haslinger C, Garin-Chesa P, Adolf GR (2009) BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 15: 3094-3102.
13. Schöffski P, Awada A, Dumez H, Gil T, Bartholomeus S, Wolter P, Taton M, Fritsch H, Glomb P, Munzert G (2012) A phase I, dose-escalation study of the novel Polo-like kinase in hibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer 48: 179-186.
14. Spankuch-Schmitt B, Bereiter-Hahn J, Kaufm ann M, Strebhardt K (2002) Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 94: 1863-1877.
15. Stadler WM, Vaughn DJ, Sonpavd e G, Vogelzang NJ, Tagawa ST, Petrylak DP, Rosen P, Lin C-C, Mahoney J, Modi S, Lee P, Ernstoff MS, Su W-C, Spira A, Pilz K, Vinisko R, Schloss C, Fritsch H, Zhao C, Carducci MA (2014) An open-label, single-arm phase II trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Cancer 120: 976-982.
16. Strebhardt K (2010) Multifaceted polo-like kinases: Drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 9: 643-660.
17. Takahashi T, Sano B, Nagata T, Kato H, Sugiyama Y, Kunieda K, Kimura M, Okano Y, Saji S (2003) Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 94: 148-152.
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216.
19. Valsasina B, Beria I, All i C, Alzani R, Avanzi N, Ballinari D, Cappella P, Caruso M, Casolaro A, Ciavolella A, Cucchi U, De Ponti A, Felder E, Fiorentini F, Galvani A, Gianellini LM, Giorgini ML, Isacchi A, Lansen J, Pesenti E, Rizzi S, Rocchetti M, Sola F, Moll J (2012) NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Mol Cancer Ther 11 : 1006-1016.